ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 39.8 | 61.0 | 34.2 |
| Other income | 2.0 | 1.3 | 2.3 |
| Total income | 41.8 | 62.3 | 36.5 |
| Profit before exceptional items & tax | 4.9 | 5.0 | 5.9 |
| Profit before tax | 4.9 | 4.7 | 5.9 |
| Net profit | 4.7 | 4.5 | 5.0 |
| Operating margin | 11.7% | 7.5% | 16.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -6.00% |
|---|---|
| Net profit, quarter on quarter | +4.40% |
| Revenue, year on year | +16.40% |
| Operating profit, year on year | -19.40% |
| Operating profit, quarter on quarter | -21.60% |
BSE results filing, NSE: GENNEX. Figures extracted from the filing.
Gennex Laboratories Ltd: key numbers
- Share price
- ₹9.10
- Market cap
- ₹221.1 Cr
- Revenue (annual)
- ₹172.7 Cr
- Net profit (annual)
- ₹20.98 Cr
- P/E (TTM)
- 9.3×Sector 43.8×
- Promoter holding
- 23.63%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gennex Laboratories Ltd
All →Gennex Laboratories Board Meeting Date
Gennex Laboratories will hold a board meeting on November 14, 2026. The board will consider unaudited financial results for the quarter ended September 30, 2026.
Gennex Laboratories Other Announcement
Gennex Laboratories Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Gennex Laboratories Management Change
Gennex Laboratories announced the appointment of Mr. Dipankar Dasgupta as Independent Director, replacing Mr. Amudala Sreeramulu Nageswar Rao, effective October 1, 2026.
Gennex Laboratories Annual General Meeting
Gennex Laboratories Limited held its 41st electronic Annual General Meeting on September 30, 2026. Proceedings included the adoption of financial statements and appointment of company directors.
Gennex Laboratories Business Update
Subsidiary Deccan Remedies Ltd received approvals from the Drug Control Administration, Andhra Pradesh, to manufacture ten additional pharmaceutical products and test licences at its facility.
Gennex Laboratories Annual General Meeting
Gennex Laboratories Limited announced the closure of its register of members from September 23 to September 30, 2026. This is for the upcoming 41st Annual General Meeting.